This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone September 2026 quarter: nil revenue, Rs 0.622 million loss after tax
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue from operations was nil in the quarter ended September 30, 2026, versus Rs 5.257 million a year earlier, while profit after tax was a loss of Rs 0.622 million versus profit of Rs 0.980 million. The review report was qualified because GST records were unavailable. Standalone half-year revenue was Rs 0.746 million and net loss Rs 0.412 million; operating cash flow was negative Rs 63,180.
The nil quarter revenue, quarterly loss, qualified GST review and negative cash flow point to high financial and reporting risk for shareholders.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.53 Cr | −100.0% |
| Operating profit | −₹0.06 Cr | ₹0.10 Cr | −163.6% |
| Profit after tax | −₹0.06 Cr | ₹0.10 Cr | −163.6% |
| EBITDA margin | — | 18.7% | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.